Cholinergic Drugs for Alzheimer's Disease

From Central Cholinergic Neurotransmission to Drug Therapies and Natural Products with Multitarget Actions

Häftad, Engelska, 2026

2 579 kr

Kommande

Cholinergic Drugs for Alzheimer’s Disease: From Central Cholinergic Neurotransmission to Drug Therapies and Natural Products with Multitarget Actions addresses the urgent need for advanced resources in neuropharmacology. The first section presents mechanistic insights into cholinergic drugs, current hypotheses for Alzheimer’s Disease progression, neurotransmitter systems, receptor biology, and the evolution of acetylcholinesterase inhibitors, including hybrid and multi-target drugs. It also covers clinical status, neuromuscular blockers, non-adrenergic neurotransmitters, protein kinase inhibitors, inflammation modulation, NMDA antagonism, biomarkers, and AI-assisted drug discovery.

The second section explores natural alkaloidal and non-alkaloidal compounds, molecular docking, SAR analysis, and daily consumable resources, with the third section investigating marine-derived AChE inhibitors, dual- and multi-target drug concepts, and emerging therapeutic compounds. This book equips the scientific community with a robust foundation for understanding and innovating in Alzheimer’s Disease therapy. By integrating molecular biology, pharmacology, and computational approaches, it empowers researchers and clinicians to address treatment challenges, optimize drug design, and leverage natural products for multifactorial intervention.

Explores cholinesterase inhibitors for cognitive improvement
Summarizes receptor mechanisms in cholinergic transmission
Reviews marine and plant-derived AChE inhibitors for innovative treatments
Presents emerging drug therapies and multitarget natural compounds for Alzheimer’s Disease

Produktinformation

Utgivningsdatum2026-06-01
Mått152 x 229 x undefined mm
Vikt450 g
FormatHäftad
SpråkEngelska
Antal sidor375
FörlagElsevier Science
ISBN9780443458446

Tillhör följande kategorier

Dr. Cheorl-Ho Kim is Professor and Chair of the Department of Biological Sciences, College of Science, Sungkyunkwan University in South Korea. He is also Professor at the Samsung Advanced Institute of Health Science and Technology (SAIHST), South Korea. Dr. Kim obtained his MS and PhD from the University of Tokyo, Japan. Prior academic appointments include Genome Program Head, Korea Research Institute of Bioscience and Biotechnology, and Chairman of the Department of Biochemistry and Molecular Biology, Dongguk University, South Korea. Dr. Kim’s research interests include neurological health, neuroinflammation, oncogenesis, and cancer metastasis.

Section I. Cholinergic drugs for Alzheimer’s Disease: Mechanisms, emerging and future evolution1. Introduction2. Current hypothesis for Alzheimer’s Disease progression3. Neurotransmitter (NT) systems and peripheral nerve system (PNS)4. ACh receptors in Ach transmission5. Choline esterase6. Cholinergic ACh, AChE, and its inhibitors7. Classification of ChE inhibitors by binding mode8. Classification of ChE inhibitors by activation mechanism9. Clinical status of ChE inhibitors10. ChE inhibitors11. Forthcoming generation of AChE inhibitors12. Hybrid inhibitors13. AChE-targeted drugs for Alzheimer’s Disease treatment14. Cholinergic neuromuscular junction and its blocking agents (blockers)15. Non-adrenergic and non-cholinergic (NANC) neurotransmitters16. Protein kinase inhibitors for treatment of Alzheimer’s Disease17. Inhibition of cholinergic inflammation via AChE inhibitor interaction with α4β2 nAChE and α7nAChR, not AChE enzyme inhibition18. NMDA and non-NMDA receptor antagonism for Alzheimer’s Disease treatment19. Challenges in recent Alzheimer’s Disease therapeutic approaches20. Identification and application of biomarkers for Alzheimer’s Disease21. Artificial Intelligence (AI)-assisted Alzheimer’s Disease target and drug discovery22. Conclusion and perspectivesSection II. Natural alkaloidal and non-alkaloidal anti-AChE and anti-Alzheimer’s Disease compounds in the symptomatic intimation of Alzheimer’s Disease23. Introduction24. Current bioactive molecules in Alzheimer’s Disease therapy25. Emerging lead compounds from natural bioactive molecules for Alzheimer’s Disease therapy26. Natural anti-AChE compounds for Alzheimer’s Disease therapy27. Molecular docking simulation for consistency between SAR results and in vitro AChE inhibitory activities28. Conceptual search for MTDs of natural plant compounds for multifactorial Alzheimer’s Disease therapy29. AChE inhibitors of daily-consumable cereals and food resources30. Conclusion and perspectivesSection III. Marine AChE inhibitors for the symptomatic treatment of Alzheimer’s Disease31. Introduction32. Localization, structure and cellular function of AChE33. AChE inhibitors from marine resources34. Non-ChE inhibitory anti-Alzheimer’s Disease compounds35. Emerging concept of dual-target drug (DTD) and multi-target drug (MTD) in Alzheimer’s Disease pathology and promising Alzheimer’s Disease drugs36. Conclusion and perspectives